Modelling survival in hepatocellular carcinoma

References

• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005
   Google Scholar
• Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996;34:DS197-9
   PubMed Web of Science ®Google Scholar
• Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006;42:2867-75
   PubMed Web of Science ®Google Scholar
• Latimer N. Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. NICE DSU Technical Support Document 14, 2011
   Google Scholar
• Aballea S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109:1082-9
   PubMed Web of Science ®Google Scholar
• Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med 2007;26:5557-71
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008;109:559-66
   PubMed Web of Science ®Google Scholar
• Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol 2011;22:1189-97
   PubMed Web of Science ®Google Scholar
• Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12:iii-ix, xi-162
   PubMed Web of Science ®Google Scholar
• Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-184, iii-iv
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-iv, ix-221
   Web of Science ®Google Scholar
• Connock M, Round J, Bayliss S, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess 2010;14(Suppl 1):17-21
   PubMedGoogle Scholar
• Connock M, Hyde C, Moore D. Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. Pharmacoeconomics 2011;29:827-37
   PubMed Web of Science ®Google Scholar
• Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 2003;24:682-701
   PubMedGoogle Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Muszbek N, Shah S, Carroll S, et al. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 2008;24:3559-69
   PubMed Web of Science ®Google Scholar
• PBAC. Sorafenib tosylate, tablet, 200 mg (base), Nexavar In: Document PBACFPS, ed. 2008
   Google Scholar
• NICE. Sorafenib for advanced hepatocellular carcinoma. In: Excellence NIfHaC, ed. Final appraisal determination 2009
   Google Scholar
• Perry JF, Charlton B, Koorey DJ, et al. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int 2007;27:1240-8
   PubMed Web of Science ®Google Scholar
• Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-8
   PubMed Web of Science ®Google Scholar
• Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005;20:873-81
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38
   PubMed Web of Science ®Google Scholar
• Cleves M, Gould W, Gutierrez R, Marchenko Y. An introduction to survival analysis using Stata. College Station, TX: Stata Press, 2002
   Google Scholar
• Singer J, Willett J. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford: Oxford University Press, 2003
   Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 2011;11:139
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34
   PubMed Web of Science ®Google Scholar
• Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-51
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modelling of Time to Event Data. New York: Wiley-Interscience, 1999
   Google Scholar
• Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-8
   PubMed Web of Science ®Google Scholar
• Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 2008;43:159-70
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:452-9
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91
   PubMed Web of Science ®Google Scholar
• Camma C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75
   PubMed Web of Science ®Google Scholar
• Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-18
   PubMed Web of Science ®Google Scholar
• Alacacioglu A, Somali I, Simsek I, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol 2008;38:683-8
   PubMed Web of Science ®Google Scholar
• Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-73
   PubMed Web of Science ®Google Scholar
• Schmitt-Graff A, Ertelt V, Allgaier HP, et al. Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival. Hepatology 2003;38:470-80
   PubMed Web of Science ®Google Scholar
• Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995;75:2427-34
   PubMed Web of Science ®Google Scholar
• Treiber G, Wex T, Rocken C, et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708
   PubMed Web of Science ®Google Scholar
• Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer 2008;44:1000-6
   PubMed Web of Science ®Google Scholar
• Yaghi C, Sharara AI, Rassam P, et al. Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. World J Gastroenterol 2006;12:3575-80
   PubMed Web of Science ®Google Scholar
• Helmberger T, Dogan S, Straub G, et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 2007;75:104-12
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Yamaguchi T, Hongo O, et al. Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma. Cancer 2010;116:393-9
   PubMed Web of Science ®Google Scholar
• Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007;46:446-55
   PubMed Web of Science ®Google Scholar
• Kung JW, MacDougall M, Madhavan KK, et al. Predicting survival in patients with hepatocellular carcinoma: a UK perspective. Eur J Surg Oncol 2007;33:188-94
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65
   PubMed Web of Science ®Google Scholar
• Lin CY, Kee KM, Wang JH, et al. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int 2009;29:74-81
   PubMed Web of Science ®Google Scholar
• Liu T, Yi C. Comparison between the CLIP and Okuda staging systems for prediction of survival time of patients with hepatocellular carcinoma in Eastern Taiwan. Tzu Chi Med J 2009;21:34-9
   Google Scholar
• Boag JW. The presentation and analysis of the results of radiotherapy. Br J Radiol 1948;21:128; passim
   PubMed Web of Science ®Google Scholar
• Boag J. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc Ser B (Methodological) 1949;11:15-53
   Google Scholar
• Chapman JA, Trudeau ME, Pritchard KI, et al. A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Res Treat 1992;22:263-72
   PubMed Web of Science ®Google Scholar
• Chapman JA, Lickley HL, Trudeau ME, et al. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J 2006;12:37-47
   PubMed Web of Science ®Google Scholar
• McCready DR, Chapman JA, Hanna WM, et al. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol 2000;7:416-26
   PubMed Web of Science ®Google Scholar
• Royston P. The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerl 2001;55:89-104
   Web of Science ®Google Scholar
• Baghestani AR, Hajizadeh E, Fatemi SR. Parametric model to analyse the survival of gastric cancer in the presence of interval censoring. Tumori 2010;96:433-7
   PubMed Web of Science ®Google Scholar
• Christopherson R, James KE, Tableman M, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008;107:325-32
   PubMed Web of Science ®Google Scholar
• Claret L, Girard P, Hoff PM, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009;27:4103-8
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, Ravasio R, Sobrero A, et al. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes’ C colon cancer: economic evaluation in an Italian NHS setting. Clin Drug Investig 2008;28:645-55
   PubMed Web of Science ®Google Scholar
• Gamel JW, Vogel RL, Valagussa P, et al. Parametric survival analysis of adjuvant therapy for stage II breast cancer. Cancer 1994;74:2483-90
   PubMed Web of Science ®Google Scholar
• Gamel JW, Meyer JS, Feuer E, et al. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer 1996;77:1459-64
   PubMed Web of Science ®Google Scholar
• Gamel JW, Vogel RL. Comparison of parametric and non-parametric survival methods using simulated clinical data. Stat Med 1997;16:1629-43
   PubMed Web of Science ®Google Scholar
• Koti K. Failure-time mixture models. Yet another way to establish efficacy. Drug Inform J 2001;35:1253-60
   Web of Science ®Google Scholar
• Maetani S, Tobe T, Hirakawa A, et al. Parametric survival analysis of gastric cancer patients. Cancer 1980;46:2709-16
   PubMed Web of Science ®Google Scholar
• Moghimi-Dehkordi B, Safaee A, Pourhoseingholi MA, et al. Statistical comparison of survival models for analysis of cancer data. Asian Pac J Cancer Prev 2008;9:417-20
   PubMed Web of Science ®Google Scholar
• Pourhoseingholi MA, Hajizadeh E, Moghimi Dehkordi B, et al. Comparing Cox regression and parametric models for survival of patients with gastric carcinoma. Asian Pac J Cancer Prev 2007;8:412-6
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MK, Altman DG. Visualizing length of survival in time-to-event studies: a complement to Kaplan–Meier plots. J Natl Cancer Inst 2008;100:92-7
   PubMed Web of Science ®Google Scholar
• Rutqvist LE. On the utility of the lognormal model for analysis of breast cancer survival in Sweden 1961–1973. Br J Cancer 1985;52:875-83
   PubMed Web of Science ®Google Scholar
• Benedict A, Cameron DA, Corson H, et al. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK. Pharmacoeconomics 2009;27:847-59
   PubMed Web of Science ®Google Scholar
• NICE. Final appraisal determination – Sorafenib for advanced hepatocellular carcinoma. In: (NICE) NIfHaCE, ed. 2009
   Google Scholar
• NICE. Bayer: Notice for Appeal. Appraisal by National Institute for Health and Clinical Excellence in Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
   Google Scholar
• Barraclough H, Morrell S, Arcorace M, et al. Degree-of-spread artefact in the New South Wales Central Cancer Registry. Aust N Z J Public Health 2008;32:414-16
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health 2004;7:627-35
   PubMed Web of Science ®Google Scholar
• Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 1992;87:942-51
   Web of Science ®Google Scholar
• De Boor C. A Practical Guide to Splines Revised Edition. Applied Mathematical Sciences Vol. 27. New York: Springer-Verlag, 2001
   Google Scholar
• Mohnike K, Wieners G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010;78:172-9
   PubMed Web of Science ®Google Scholar